Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Top Ten Searches
parkinson's neuritis neuralgia myasthenia gravis lactic acidosis ataxia seizure tinnitus migraine hypotoniaYour Article Summary
See Latest ArticlesTranscranial brain sonography findings predict disease progression in multiple sclerosis
Neurology, 08/07/09
Walter U et al. – Neurodegenerative disease–like deep gray matter lesions can be frequently detected by transcranial sonography (TCS) in pts with multiple sclerosis (MS). Findings suggest that TCS shows changes of brain iron metabolism that correlate with future progress of MS.
Methods- Study of whether TCS can also display deep gray matter lesions in pts with MS and of whether sonographic findings relate to severity and progression of MS
- Prospectively study of 75 pts with different courses of MS and 55 age-matched healthy subjects clinically and with TCS
- At time of TCS, 1.5-T MRI for 23 additional pts
- Clinical assessment of disease progression 2 yrs after TCS
- Abnormal hyperechogenicity of SN, lenticular nucleus (LN), caudate nucleus, and thalamus in 41%, 54%, 40%, and 8% of MS pts, with similar frequency in pts with relapsing-remitting and primary or secondary progressive MS if corrected for disease duration, but only in 13%, 13%, 5%, and none of control subjects
- Hyperechogenicity of SN and LN correlated with more pronounced MRI T2 hypointensity, possibly reflecting iron deposition
- Larger bilateral SN echogenic area related to higher rate of disease progression
- Small SN echogenic area (SN hypoechogenicity) predicted disease course without further progression within 2 yrs
Related Articles
Impact of multiple sclerosis relapses on progression diminishes with time
Neurology, 11/06/09
Relevance Score: 89%
Serum anti-GAGA4 IgM antibodies differentiate relapsing remitting and secondary progressive multiple sclerosis from primary progressive multiple sclerosis and other neurological diseases
Journal of Neuroimmunology, 11/04/09
Relevance Score: 89%
Disease progression among multiple sclerosis patients before and during a disease-modifying drug program: a longitudinal population-based evaluation
Multiple Sclerosis, 11/03/09
Relevance Score: 88%
Celiac disease, Behçet, and idiopathic thrombocytopenic purpura in siblings of a patient with multiple sclerosis
Multiple Sclerosis, 10/26/09
Relevance Score: 82%
A single-centre, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis
Multiple Sclerosis, 10/01/09
Relevance Score: 82%
Today in Demyelinating Disorders...keeping you current
Receive free subspecialty "5-minute updates" via email
Micro-ribonucleic acid profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47
Brain, 12/04/09
Dysregulated Epstein-Barr virus infection in patients with CIDP
Journal of Neuroimmunology, 12/04/09
Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: A double- blind, randomized, multicentre, placebo-controlled trial
Amyotrophic Lateral Sclerosis, 12/04/09
Sponsor
Article Search
Sponsor